Literature DB >> 17157948

A SAS macro for parametric and semiparametric mixture cure models.

Fabien Corbière1, Pierre Joly.   

Abstract

Cure models have been developed to analyze failure time data with a cured fraction. For such data, standard survival models are usually not appropriate because they do not account for the possibility of cure. Mixture cure models assume that the studied population is a mixture of susceptible individuals, who may experience the event of interest, and non-susceptible individuals that will never experience it. The aim of this paper is to propose a SAS macro to estimate parametric and semiparametric mixture cure models with covariates. The cure fraction can be modelled by various binary regression models. Parametric and semiparametric models can be used to model the survival of uncured individuals. The maximization of the likelihood function is performed using SAS PROC NLMIXED for parametric models and through an EM algorithm for the Cox's proportional hazards mixture cure model. Indications and limitations of the proposed macro are discussed and an example in the field of cancer clinical trials is shown.

Entities:  

Mesh:

Year:  2006        PMID: 17157948     DOI: 10.1016/j.cmpb.2006.10.008

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  17 in total

1.  Spontaneous Clearance of the Hepatitis C Virus Among Men Who Have Sex With Men.

Authors:  Eric C Seaberg; Mallory D Witt; Lisa P Jacobson; Roger Detels; Charles R Rinaldo; Joseph B Margolick; Stephen Young; John P Phair; Chloe L Thio
Journal:  Clin Infect Dis       Date:  2015-07-14       Impact factor: 9.079

2.  Single-arm phase II trial design under parametric cure models.

Authors:  Jianrong Wu
Journal:  Pharm Stat       Date:  2015-04-01       Impact factor: 1.894

3.  Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases.

Authors:  S Stremitzer; Y Sunakawa; W Zhang; D Yang; Y Ning; S Stintzing; A Sebio; S Yamauchi; S Matsusaka; R El-Khoueiry; J Stift; F Wrba; T Gruenberger; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2015-03-10       Impact factor: 3.550

4.  Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia.

Authors:  Markus Pfirrmann; Susanne Saussele; Andreas Hochhaus; Andreas Reiter; Ute Berger; Dieter K Hossfeld; Christoph Nerl; Christof Scheid; Karsten Spiekermann; Jiri Mayer; Andrzej Hellmann; Klaus Lechner; Christiane Falge; Herbert G Sayer; Donald Bunjes; Arnold Ganser; Dietrich W Beelen; Helen Baldomero; Urs Schanz; Hermann Heimpel; Hans-Jochem Kolb; Joerg Hasford; Alois Gratwohl; Rüdiger Hehlmann
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-10       Impact factor: 4.553

5.  smcure: an R-package for estimating semiparametric mixture cure models.

Authors:  Chao Cai; Yubo Zou; Yingwei Peng; Jiajia Zhang
Journal:  Comput Methods Programs Biomed       Date:  2012-09-25       Impact factor: 5.428

6.  A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.

Authors:  Xiaoping Xiong; Jianrong Wu
Journal:  Pharm Stat       Date:  2016-11-08       Impact factor: 1.894

7.  Sample size calculation for the proportional hazards cure model.

Authors:  Songfeng Wang; Jiajia Zhang; Wenbin Lu
Journal:  Stat Med       Date:  2012-07-11       Impact factor: 2.373

8.  Conditional modeling of antibody titers using a zero-inflated poisson random effects model: application to Fabrazyme.

Authors:  Peter L Bonate; Crystal Sung; Karen Welch; Susan Richards
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-09-30       Impact factor: 2.745

9.  Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden.

Authors:  Ruth Etzioni; Lorelei Mucci; Shu Chen; Jan-Erik Johansson; Katja Fall; Hans-Olov Adami
Journal:  Clin Cancer Res       Date:  2012-08-27       Impact factor: 12.531

10.  Sample size calculation for testing differences between cure rates with the optimal log-rank test.

Authors:  Jianrong Wu
Journal:  J Biopharm Stat       Date:  2016-02-16       Impact factor: 1.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.